names Humira and Trudexa, was approved for use in the European Union in September 2003. Marketing 1999: Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7 2001, June: Results from ARMADA, a double-blind, placebo-controlled clinical trial involving 271 patients with active rheumatoid arthritis despite treatment with methotrexate are announced. Among the results are that 50% of patients show a 50% improvement in American College of Rheumatology (ACR) score. 2002: Broke ground on a new state-of-the-art biologics manufacturing facility. 2002: Adalimumab results from five separate trials show that it is effective at reducing signs and symptoms of rheumatoid arthritis. In these studies, adalimumab had a rapid onset of action and sustained efficacy. Furthermore, adalimumab was safe and effective when given alone or in combination with MTX as a subcutaneous injection. 2002, 31 December: Humira approved by the US Food and Drug Administration (FDA) for treatment of rheumatoid arthritis. 2003: Launched Humira for rheumatoid arthritis and continued clinical studies for additional indications. 2005: Launched Humira for psoriatic arthritis. Exceeded in annual sales for the first time. 2005: Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan. 2006: Submitted Humira for the Crohn's disease indication and launched it for AS. Exceeded in annual sales. 2007: Launched Humira for Crohn's disease in the United States, submitted Humira for global regulatory approval for psoriasis — the fifth new Humira disease indication at this time, achieved more than in worldwide Humira sales. 2007: Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico 2008: Launched Humira for plaque psoriasis 2009: Five-Year Data Demonstrate Initial Use of Humira Plus Methotrexate May Prevent Further Joint Damage in Early Rheumatoid Arthritis Patients 2012: Humira could be associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease 2013: Due to the split of Abbott, Humira rights are now owned by AbbVie. 2014: Humira recognized by IMS Health as the "world's best selling drug." 2014: In December 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia. 2015: Launched Humira for moderate to severe hidradenitis suppurativa, an orphan indication. No other treatment has been rigorously tested and found to be safe and effective in treating this painful and scarring condition. 2016: The best-selling drugs list published by Genetic Engineering